The dataset contains all variables of interest presented in the study. By downloading and using these data, you agree that you will cite the appropriate publication in any communications or publications arising directly or indirectly from these data; for utilization of data available prior to publication, you agree to respect the requested responsibilities of resource users under 2003 Fort Lauderdale principles; you agree that you will never attempt to identify any participant.

When using downloaded data, please cite corresponding paper and this repository:

John D. Groarke MBBCh et al. (2024) Autonomic dysfunction among adult survivors of childhood cancer in the St. Jude Lifetime Cohort Study, JACC: CardioOncology. Available at: https://www.sciencedirect.com/science/article/pii/S2666087324002825

Funding:

IntroductionThe role of age and sex in the presentation and outcome of endemic Burkitt lymphoma (BL) has not been studied recently. This study analysed these factors in 934 patients with BL who had received cyclophosphamide and intrathecal methotrexate as treatment.MethodsRecords of 934 children diagnosed with BL from 2004 to 2015 were obtained from our Paediatric Oncology Networked Database (POND) cancer registry. Age at diagnosis, sex, disease stage, time to diagnosis, delay in diagnosis, completion of treatment, rate of abandonment, and one-year survival rates were recorded and statistically analysed.ResultsThe male to female ratio of 1.41 for the study population of 934. The median delay from onset of symptoms to diagnosis was 31 days. The St Jude stage distribution was I = 6.4%, II = 5.9%, III = 71.5% and IV = 16.2%. Significantly more patients presented with stage III disease in age groups 5–9 and 10–14 years than 0–4 years. The overall 1-year survival rate was 53.45%, respectively 77.1% for stage I, 67.9% for stage II, 55.1% for stage III and 32.4% for stage IV disease (p

E00086497, Portsmouth demographics statistics broken down by ethnicity, religion, age, birthplace and much more. View full insights for the local and surrounding households.

Portsmouth 024, Portsmouth demographics statistics broken down by ethnicity, religion, age, birthplace and much more. View full insights for the local and surrounding households.

IntroductionAcute lymphoblastic Leukemia (ALL) is the most common pediatric malignancy. While the survival rate for childhood ALL exceeds 90% in high-income countries, the estimated survival in low-and middle-income countries ranges from 22-79%, depending on the region and local resources.MethodsThis study retrospectively reviewed demographic, biological, and clinical parameters of children under 18 years of age with newly diagnosed ALL presenting between 2013-2017 across five pediatric centers in 4 countries in South America. Survival analyses were estimated using the Kaplan-Meier method.ResultsAcross the five centers, 752 patients were analyzed (Bolivia [N=9], Ecuador [N=221], Paraguay [N=197], Peru [N=325]) and 92.1% (n=690) patients were diagnosed with B-cell and 7.5% (n= 56) with T-cell ALL. The median age was 5.5 years old (IQR 7.29). At diagnosis, 47.8% of patients were categorized as standard and 51.9% as high risk per their institutional regimen. Advanced diagnostics availability varied between modalities. MRD was evaluated in 69.1% of patients; molecular testing was available for ETV6-RUNX, BCR-ABL1, TCF3-PBX1, and KMT2A-rearranged ALL in 75-81% of patients; however, karyotyping and evaluation for iAMP21 were only performed in 42-61% of patients. Central nervous system (CNS) involvement was evaluated at diagnosis in 57.3% (n=429) patients; of these, 93.7% (n=402) were CNS 1, 1.6% (n=7) were CNS 2, 0.7% (n=11) were CNS3, 1.9% (n=8) had cranial nerve palsy, and 2.1% (n=9) results unavailable. Chemotherapy delays >2 weeks were reported in 56.0% (n=421) patients during treatment. Delays were attributed to infection in 63.2% (n=265), drug-related toxicities in 47.3% (n=198), and resource constraints, including lack of bed availability in 23.2% (n=97) of patients. The 3-year Abandonment-sensitive EFS and OS were 61.0±1.9% and 67.2±1.8%, respectively. The 3-year EFS and OS were 71.0±1.8% and 79.6±1.7%, respectively.DiscussionThis work reveals opportunities to improve survival, including addressing severe infections, treatment interruptions, and modifications due to drug shortages. In 2018, healthcare professionals across South America established the Pediatric Oncology Latin America (POLA) group in collaboration with St. Jude Children’s Research Hospital. POLA collaborators developed an evidence-based, consensus-derived, adapted treatment guideline, informed by preliminary results of this evaluation, to serve as the new standard of care for pediatric ALL in participating institutions.

This is a dataset corresponding to data utilized in the publication titled "Social cognition and adjustment in adult survivors of pediatric central nervous system tumors" reported in Papini et al., 2023 (DOI: 10.1002/cncr.34889).

The file contains:

• demographic variables: sex and age at assessment (in years)
• clinical variables: clinical group, age at diagnosis (in years), time since diagnosis (in years), intelligence score (in standard score), tumor location, dose of cranial radiation (in Gy), chemotherapy agents (yes/no) and doses (in mg/m²), neurosurgery type, diagnosis, and presence of stoke, seizure and hearing loss
• functional outcomes: independent living, marital status, education, and employment
• social cognition measures (in scaled scores): Social Perception, Affect Naming, Prosody, Prosody Pair Matching, Faces Immediate, Faces Delayed, Faces Content, Faces Spatial, Names Immediate, Names Delayed, Proper Names, Activity
• social adjustment measures (in T-scores): Companionship, Instrumental Support, Emotional Support, Informational Support, Social Isolation, Ability to Participate in Social Roles and Activities, and Satisfaction with Social Roles and Activities
• neurocognitive functioning measures: executive function impairment (yes/no), non-verbal reasoning impairment (yes/no) and the BRIEF Global Executive Composite score (in T-score)

Please note that the time variables (i.e., age at assessment, age at diagnosis, and time since diagnosis) were rounded to whole years to ensure deidentification for sharing purposes.

Please cite the appropriate publications (this repository and corresponding publication above) in any communications or publications arising directly or indirectly from these data.

Funding

The study was supported by National Cancer Institute (U01 CA195547, Hudson and Ness) and St. Baldrick’s Foundation (Research Scholar Award, Brinkman). Support to St Jude Children’s Research Hospital was also provided by the National Cancer Institute Cancer Center Support Grant (CORE) Grant (P30 CA21765, Roberts) and the American Lebanese Syrian Associated Charities.

https://www.cancerimagingarchive.net/wp-content/uploads/nctn-logo-300x108.png" alt="" width="300" height="108" />

Demographic Summary of Available Imaging

Characteristic	Value (N = 108)
Age (months)	Mean ± SD: 171.4 ± 35 Median (IQR): 180 (153.8-197) Range: 40-223
Sex	Male: 74 (69%) Female: 34 (31%)
Race	White: 41 (38%) Black: 52 (48%) Asian: 3 (3%) American Indian/Alaska Native: 1 (1%) Native Hawaiian or other Pacific Islander: 2 (2%) Unknown: 9 (8%)
Ethnicity	Hispanic: 12 (11%) Non-Hispanic: 93 (86%) Unknown: 3 (3%)

This collection contains data from the Children’s Oncology Group (COG) Clinical Trial NCT00274937, “Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer". Principal Investigator: Carlos Rodriguez-Galindo, MD. It was sponsored by NCI and performed by the Children's Oncology Group under study number ARAR0331. This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as amifostine, may protect normal cells from the side effects of radiation therapy. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with amifostine and chemotherapy may kill more tumor cells. Select patient-level data from this trial is available via the following link: https://nctn-data-archive.nci.nih.gov/node/1302.

Trial Outcomes

Results of the trial have been reported in the following publications:

• Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, Campana D, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Khan RB, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV, Pui CH. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019 Dec 10;37(35):3377-3391. doi: 10.1200/JCO.19.01692. Epub 2019 Oct 28.
• Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. J Clin Oncol. 2019 Dec 10;37(35):3369-3376. doi: 10.1200/JCO.19.01276. Epub 2019 Sep 25. Erratum in: J Clin Oncol. 2021 May 10;39(14):1602.

Portsmouth 025a, Portsmouth demographics statistics broken down by ethnicity, religion, age, birthplace and much more. View full insights for the local and surrounding households.

Portsmouth 025b, Portsmouth demographics statistics broken down by ethnicity, religion, age, birthplace and much more. View full insights for the local and surrounding households.

E00086488, Portsmouth demographics statistics broken down by ethnicity, religion, age, birthplace and much more. View full insights for the local and surrounding households.